Cubist Systematic Strategies LLC Purchases New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Cubist Systematic Strategies LLC bought a new position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 281,410 shares of the biotechnology company's stock, valued at approximately $2,561,000. Cubist Systematic Strategies LLC owned approximately 0.50% of Astria Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in shares of Astria Therapeutics by 4.1% during the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock worth $595,000 after purchasing an additional 2,556 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company's stock worth $70,000 after buying an additional 2,861 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,112 shares during the last quarter. American International Group Inc. raised its position in shares of Astria Therapeutics by 49.4% during the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company's stock valued at $346,000 after buying an additional 8,122 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Astria Therapeutics by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock worth $1,266,000 after acquiring an additional 8,965 shares during the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ATXS shares. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, September 27th. Oppenheimer lifted their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 13th. TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a "buy" rating and a $35.00 price target for the company. Wedbush reiterated an "outperform" rating and issued a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Finally, Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $25.20.

Astria Therapeutics Trading Up 10.7 %

Shares of ATXS stock traded up $1.12 during mid-day trading on Friday, reaching $11.62. The stock had a trading volume of 355,085 shares, compared to its average volume of 665,530. The firm has a market capitalization of $638.09 million, a PE ratio of -5.01 and a beta of 0.71. The stock's 50-day moving average price is $11.29 and its two-hundred day moving average price is $10.56. Astria Therapeutics, Inc. has a 52-week low of $4.26 and a 52-week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). On average, equities research analysts forecast that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.